A. Kanerva

Publications166
h-index45
Citations5,719
Highly Influential Citations174
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • Akseli Hemminki
  • 311 Publications, 14,328 Citations
  • D. Curiel
  • 888 Publications, 37,716 Citations
  • V. Cerullo
  • 128 Publications, 3,873 Citations
  • S. Pesonen
  • 94 Publications, 3,115 Citations
  • Publications
  • Influence
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
Granulocyte macrophage colony-stimulating factor (GMCSF) can mediate antitumor effects by recruiting natural killer cells and by induction of tumor-specific cytotoxic T-cells through… Expand
  • 193
  • 13
  • PDF
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
Promising clinical results have been achieved with monoclonal antibodies (mAbs) such as ipilimumab and tremelimumab that block cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, CD152). However,… Expand
  • 106
  • 13
  • PDF
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Augmenting antitumor immunity is a promising way to enhance the potency of oncolytic adenoviral therapy. Granulocyte-macrophage colony-stimulating factor (GMCSF) can mediate antitumor effects by… Expand
  • 207
  • 9
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.
Gene delivery efficiency in clinical cancer gene therapy trials with recombinant adenoviruses (Ads) based on serotype 5 (Ad5) has been limited partly because of variable expression of the primary Ad5… Expand
  • 276
  • 8
  • PDF
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
Patients with advanced solid tumors refractory to and progressing after conventional therapies were treated with three different regimens of low-dose cyclophosphamide (CP) in combination with… Expand
  • 125
  • 8
  • PDF
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.
Oncolytic viruses that are replication competent in tumor but not in normal cells represent a novel approach for treating neoplastic diseases. However, the oncolytic potency of replicating agents is… Expand
  • 174
  • 6
  • PDF
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Oncolytic adenovirus is an attractive platform for immunotherapy because virus replication is highly immunogenic and not subject to tolerance. Although oncolysis releases tumor epitopes and provides… Expand
  • 130
  • 6
  • PDF
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Oncolytic adenoviruses and certain chemotherapeutics can induce autophagy and immunogenic cancer cell death. We hypothesized that the combination of oncolytic adenovirus with low-dose temozolomide… Expand
  • 120
  • 5
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.
The immunosuppressive environment of advanced tumors is a primary obstacle to the efficacy of immunostimulatory and vaccine approaches. Here, we report an approach to arm an oncolytic virus with CD40… Expand
  • 119
  • 4
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy
Oncolytic viruses that selectively replicate in tumor cells can be used for treatment of cancer. Accumulating data suggests that virus induced oncolysis can enhance anti-tumor immunity and break… Expand
  • 59
  • 4
  • PDF